Mapping of Ulcerative Colitis Samples against Consensus Molecular Subgroups for Colorectal Cancer Demonstrates Potential to Identify At-Risk Ulcerative Colitis Patients.
AuthorsScanlon EE 1 , Kennedy RD 1,2, Blayney JK1
Departments / Institutions1Center for Cancer Research and Cell Biology, Queen’s University Belfast, 97 Lisburn Road, Belfast, BT97AE 2Almac Diagnostics, 19 Seagoe Industrial Estate, Craigavon, BT635QD
Publication DateAutumn 2017
Inflammatory bowel disease (IBD), specifically ulcerative colitis (UC) is a pre-disposing factor for colorectal cancer (CRC), with risk increasing with disease duration. CRC patients previously diagnosed with UC have poorer prognosis compared to sporadic CRC.
Through the integration of UC, CRC and normal tissue transcriptional profiles, we aim to identify at-risk patients through characterising a novel UC/CRC molecular subgroup. By identifying underpinning multiple drivers of disease behaviour, we will evaluate preventative/intervention treatments for UC/CRC at-risk patients and determine if a prior history of UC indicates additional CRC treatments.
Publically-available transcriptional data and a novel in silico technique, Gene Expression Compositional Assignment, were used to consider similarities between UC/UC-CRC patients with normal/CRC samples and corresponding consensus molecular subgroups (CMS) groups. The microenvironment cell population (MCP) counter was used to assess cell-type proportions.
UC/CRC samples were significantly more similar to sporadic CRC than normal/quiescent UC samples (p = 0.0001), with the majority of these alignments to metastasized tumours (Fig 1). CMS3 and CMS2 alignments were over- and under-represented respectively. The majority of UC-CRC samples aligned to the CMS unclassified group; which had significantly different high stromal and immune contents by MCP.
Initial results show this approach has potential to identify UC patients at-risk of developing CRC. CMS unclassified is an intermediate between the poorest prognosis groups, CMS1 and CMS4, with high immune and stromal scores. This corresponds with the UC stromal phenotype being more aggressive holding potential to connecting UC with CRC progression.
Event takes place on June 9, 2022 until June 10, 2022
Download our latest Documents